Advertisement

Person › Details
John Dawson (Oxford Biomedica plc (LSE: OXB))
Dawson, John (Oxford BioMedica 200810– CEO before Cephalon Europe)
![]() |
Organisation | Oxford Biomedica plc (LSE: OXB) |
Group | Oxford Biomedica (Group) | |
Former/major organisation | Cephalon Europe | |
Today | Teva (Group) | |
Group | Teva (Group) | |
![]() |
Product | TroVax® |
Product 2 | ProSavin® | |
Record changed: 2020-11-10 |
Advertisement

More documents for John Dawson
- [1] PhoreMost Ltd.. (11/9/20). "Press Release: PhoreMost and Oxford Biomedica Enter Gene Therapy Discovery Collaboration". Cambridge & Oxford....
- [2] Oxford BioMedica plc. (9/1/20). "Press Release: Oxford Biomedica Signs Supply Agreement with AstraZeneca to Expand Manufacturing Support of COVID-19 Vaccine Candidate, AZD1222". Oxford....
- [3] Oxford Biomedica plc. (6/8/20). "Press Release: Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre". Oxford....
- [4] Oxford Biomedica plc. (3/18/20). "Press Release: Building the Group for Future Growth. Business Update". Oxford....
- [5] Oxford Biomedica plc. (3/18/20). "Press Release: Oxford BioMedica Signs License & Clinical Supply Agreement with Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, for LentiVector Platform for CAR-T and TCR-T Therapeutics". Oxford....
- [6] Oxford Biomedica plc. (5/28/19). "Press Release: Oxford BioMedica Announces Strategic Investment by Novo Holdings A/S". Oxford....
- [7] Oxford Biomedica plc. (3/14/19). "Press Release: Oxford Biomedica plc Preliminary Results for the Year Ended 31 December 2018". Oxford....
- [8] Oxford Biomedica plc. (2/7/19). "Press Release: Oxford Biomedica Provides Update on Programmes Outlicensed to Sanofi". Oxford....
- [9] Oxford Biomedica plc. (11/23/18). "Press Release: Oxford BioMedica Announces New Digital Framework Initiative to Streamline the Production of Next-generation Medicines with Cash Injection from Innovate UK". Oxford....
- [10] Boehringer Ingelheim. (8/6/18). "Press Release: Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis". Ingelhei...
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top